Financial reports
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
25 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
Current reports
8-K
Entry into a Material Definitive Agreement
2 Apr 24
8-K
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
2 Apr 24
8-K
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
25 Mar 24
8-K
Other Events
9 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Entry into a Material Definitive Agreement
27 Nov 23
8-K
Departure of Directors or Certain Officers
21 Nov 23
8-K
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
13 Nov 23
8-K
Entry into a Material Definitive Agreement
4 Oct 23
8-K
Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
10 Aug 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
2 Apr 24
S-8
Registration of securities for employees
27 Feb 24
424B5
Prospectus supplement for primary offering
9 Feb 24
S-3
Shelf registration
13 Nov 23
S-8
Registration of securities for employees
27 Feb 23
S-8
Registration of securities for employees
31 Aug 22
POS EX
Additional exhibits for listing
18 May 22
S-8
Registration of securities for employees
28 Feb 22
POS AM
Prospectus update (post-effective amendment)
28 Feb 22
POSASR
Automatic shelf registration (post-effective amendment)
28 Feb 22
Proxies
DEF 14A
Definitive proxy
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
DEFA14A
Additional proxy soliciting materials
22 Apr 22
DEF 14A
Definitive proxy
22 Apr 22
DEF 14A
Definitive proxy
29 Apr 21
DEF 14A
Definitive proxy
24 Apr 20
DEF 14A
Definitive proxy
26 Apr 19
Other
EFFECT
Notice of effectiveness
22 Nov 23
CORRESP
Correspondence with SEC
17 Nov 23
UPLOAD
Letter from SEC
16 Nov 23
EFFECT
Notice of effectiveness
20 May 22
EFFECT
Notice of effectiveness
15 Oct 19
CORRESP
Correspondence with SEC
9 Oct 19
UPLOAD
Letter from SEC
8 Oct 19
CT ORDER
Confidential treatment order
27 Sep 18
EFFECT
Notice of effectiveness
26 Sep 18
CORRESP
Correspondence with SEC
24 Sep 18
Ownership
4
Venkatesh Srinivasan
12 Apr 24
SC 13G
Point72 Asset Management, L.P.
5 Apr 24
4/A
WILLIAM J NEWELL
22 Mar 24
4/A
LINDA A FITZPATRICK
22 Mar 24
4/A
EDWARD C ALBINI
22 Mar 24
4
LINDA A FITZPATRICK
7 Mar 24
4
Venkatesh Srinivasan
7 Mar 24
4
WILLIAM J NEWELL
7 Mar 24
4
Hans-Peter Gerber
7 Mar 24
4
Jane Chung
7 Mar 24